This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.

The statistics are sobering: over 200,000 men in the United States are diagnosed with prostate cancer every year. With this diagnosis, men are expected to psychologically combat the worry, practical concerns, and the emotional and physical changes during an immensely trying time. How to help? In Managing Prostate Cancer: A Guide for Living Better, Dr. Andrew J. Roth, a psychiatrist specializing in psychological support for cancer patients, provides the emotional skills and strategies necessary to help patients deal with the challenges a prostate cancer diagnosis brings to everyday life. These tools, which Dr. Roth terms "Emotional Judo," effectively teach patients to identify what their fears are rooted in, how to distinguish the rational and irrational aspects of their thoughts and behaviors, make healthier choices to promote a more positive approach, and ultimately transform their lives into a more fulfilling and peaceful journey.

Although much progress has been made in the four years since the first edition of Management of Prostate Cancer, prostate cancer remains a significant biological, me- cal, and personal challenge for millions of men. In this interval, some important trends and observations have emerged that represent real progress in the field and which will shape the direction of clinical practice and research in the next 5–10 years. These obs- vations include: (1) a decline in prostate-related cancer mortality in the United States, likely owing to a combination of factors including screening, more aggressive and earlier therapy, and improvements in specific therapies; (2) a significant downward pathological stage migration, so that an individual’s chance of cure for a given stage, grade, and PSA is better now than it was early in the PSA era, even without associated improvements in individual therapies; (3) the recognition of new PSA isoforms that may refine screening strategies; (4) several randomized, phase III clinical trials demonstrating survival adv- tages of one form of therapy over another in selected populations (external beam rad- therapy with adjuvant hormones vs radiotherapy alone, radical prostatectomy vs observation); (5) a focus on the biology of bone and bone metastasis, and new agents that reduce skeletal-related events and which may inhibit the growth of new metastases; (6) second-generation anti-PSMA antibodies with improved potential for imaging and therapy; (7) the development and widespread adoption of nomograms that assist in cli- cal decision-making for individual patients; (8) the identification of new genes that

Looks at the effectiveness of the prostatectomy and surveys the latest research in prostate cancer managment.

Do you manage patients with prostate cancer? Could you use an expert guide examining all possible management options? Prostate Cancer: diagnosis and clinical management providesurologists and oncologists of all levels with up-to-date, evidence-based guidance to the diagnosis, treatment and clinical management of a disease which accounts for a quarter of all cancers affecting men. Designed to be as practical and accessible as possible, leading experts discuss key issues in prostate cancer management and examine how to deliver best practice in the clinical care of their patients. Topics covered include: What must be considered when counseling newly-diagnosed cancer patients Radical surgery options for prostate cancer Novel therapies for localized prostate cancer How should metastatic prostate cancer be diagnostic and managed What are the best methods of administering end of life care for the patient Brought to you by a highly experienced editor team, and containing key points, management algorithms, practice tips and the latest AUA and EAU clinical guidelines, this is the ideal consultation tool for doctors both on the wards and in the office.

The statistics are sobering: over 200,000 men in the United States are diagnosed with prostate cancer every year. With this diagnosis, men are expected to psychologically combat the worry, practical concerns, and the emotional and physical changes during an immensely trying time. How to help? In Managing Prostate Cancer: A Guide for Living Better, Dr. Andrew J. Roth, a psychiatrist specializing in psychological support for cancer patients, provides the emotional skills and strategies necessary to help patients deal with the challenges a prostate cancer diagnosis brings to everyday life. These tools, which Dr. Roth terms "Emotional Judo," effectively teach patients to identify what their fears are rooted in, how to distinguish the rational and irrational aspects of their thoughts and behaviors, make healthier choices to promote a more positive approach, and ultimately transform their lives into a more fulfilling and peaceful journey.

Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.